Inhibitory Effect of Anti-rheumatic Drug Iguratimod for Hepatocellular Carcinogenesis by Inhibition of Serum Interleukin-8 Production

被引：0
|
作者：
Sakamoto, Taro [1 ]
Ishii, Yuji [1 ]
Shiba, Hiroaki [1 ]
Furukawa, Kenei [1 ]
Fujiwara, Yuki [1 ]
Haruki, Koichiro [1 ]
Iwase, Ryota [1 ]
Shirai, Yoshihiro [1 ]
Yanaga, Katsuhiko [1 ]
机构：
[1] Jikei Univ, Sch Med, Dept Surg, Tokyo, Japan
来源：
ANTICANCER RESEARCH | 2016年 / 36卷 / 07期
关键词：
Hepatocellular carcinoma; rat; interleukin-8; iguratimod; KAPPA-B ACTIVATION; HEPATITIS-B; CYTOKINE PRODUCTION; CURATIVE RESECTION; CARCINOMA; CANCER; CELLS; EXPRESSION; THERAPY; GENE;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Aim: Angiogenesis is a known factor for the development of hepatocellular carcinoma (HCC). The aim of this study was to assess the property of iguratimod, that is an anti-inflammatory drug for rheumatoid arthritis, on anti-angiogenesis and anti-carcinogensis for HCC. Materials and Methods: In vitro, human umbilical vein endothelial cells were cultured under interleukin-8 (IL-8) with or without iguratimod. In vivo, a rat model with HCC received iguratimod or distilled water for 6 weeks. Diameter of the largest tumor, number of tumors and serum interleukin-8 concentration were compared between iguratimod and control groups. Results: By an in vitro angiogenesis assay, it was found angiogenesis in iguratimod group was significantly lower than that in control group (p=0.013). In vivo, largest tumor diameter (p=0.036), number of the tumor (p=0.011) and serum interleukin-8 concentration (p=0.036) in the iguratimod group were significantly smaller and lower than those in the control group. Conclusion: Iguratimod may inhibit hepatocellular carcinogensis by inhibition of interleukin-8 production in a rat model.
引用
收藏
页码：3301 / 3306
页数：6
相关论文
共 31 条
  • [21] Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients
    Ishikawa, Koichiro
    Ishikawa, Junichiro
    MODERN RHEUMATOLOGY, 2019, 29 (03) : 418 - 429
  • [22] Metronidazole-flavonoid derivatives as anti-Helicobacter pylori agents with potent inhibitory activity against HPE-Induced interleukin-8 production by AGS cells
    Li, Huan-Qiu
    Xu, Chen
    Li, Hong-Sen
    Xiao, Zhu-Ping
    Shi, Lei
    Zhu, Hai-Liang
    CHEMMEDCHEM, 2007, 2 (09) : 1361 - 1369
  • [23] Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4+ T cells from the Th1 to the Th2 pathway
    Kim, TS
    Kang, BY
    Lee, MH
    Choe, YX
    Hwang, SY
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (03) : 571 - 578
  • [24] The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes
    Takuma Kusabe
    Yuko Waguri-Nagaya
    Tomohiro Tanikawa
    Mineyoshi Aoyama
    Muneyoshi Fukuoka
    Masaaki Kobayashi
    Takanobu Otsuka
    Kiyofumi Asai
    Rheumatology International, 2005, 25 : 625 - 630
  • [25] The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes
    Kusabe, T
    Waguri-Nagaya, Y
    Tanikawa, T
    Aoyama, M
    Fukuoka, M
    Kobayashi, M
    Otsuka, T
    Asai, K
    RHEUMATOLOGY INTERNATIONAL, 2005, 25 (08) : 625 - 630
  • [26] The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors
    Martinez-Feito, Ana
    Plasencia-Rodriguez, Chamaida
    Navarro-Compan, Victoria
    Hernandez-Breijo, Borja
    Angeles Gonzalez, Maria
    Monjo, Irene
    Nuno, Laura
    Nozal, Pilar
    Pascual-Salcedo, Dora
    Balsa, Alejandro
    CLINICAL RHEUMATOLOGY, 2019, 38 (03) : 949 - 954
  • [27] The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors
    Ana Martínez-Feito
    Chamaida Plasencia-Rodríguez
    Victoria Navarro-Compán
    Borja Hernández-Breijo
    María Ángeles González
    Irene Monjo
    Laura Nuño
    Pilar Nozal
    Dora Pascual-Salcedo
    Alejandro Balsa
    Clinical Rheumatology, 2019, 38 : 949 - 954
  • [28] THE INHIBITORY EFFECT OF SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS AND STEROIDS ON GLIOSTATIN/PLATELET-DERIVED ENDOTHELIAL CELL GROWTH FACTOR PRODUCTION IN HUMAN FIBROBLAST-LIKE SYNOVIOCYTES
    Kawaguchi, Y.
    Waguri-Nagaya, Y.
    Ikuta, K.
    Tatematsu, N.
    Kobayashi, M.
    Goto, H.
    Nozaki, M.
    Aoyama, M.
    Asai, K.
    Otsuka, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 917 - 918
  • [29] THE EFFECT OF INHIBITION OF LEUKOTRIENE-B4 RELEASE ON LIPOPOLYSACCHARIDE-INDUCED PRODUCTION OF NEUTROPHIL ATTRACTANT ACTIVATION PROTEIN-1 (INTERLEUKIN-8) BY HUMAN ALVEOLAR MACROPHAGES
    RANKIN, JA
    HARRIS, P
    PROSTAGLANDINS, 1993, 45 (01): : 77 - 84
  • [30] KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-α and interleukin-1β in THP-1, a human monocyte cell line
    Sugimoto, M
    Inoue, T
    Yamashita, M
    Takeshita, K
    Nakaike, S
    DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 2002, 28 (05) : 197 - 205
1234